Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204223881> ?p ?o ?g. }
- W3204223881 endingPage "121148" @default.
- W3204223881 startingPage "121148" @default.
- W3204223881 abstract "The present study aimed to synthesize cholesteryl acetyl carnitine (CAC), and surface modify the PEGylated liposomes with the intention of enhanced cancer cell uptake. For this, CAC synthesis was performed in amine-free esterification conditions and then four liposomal formulations of unmodified, CAC/PEG, and CAC + PEG-modified were prepared by ethanol injection method. Cytotoxicity of the liposomes was investigated in A549 cells, followed by cellular uptake assessments of coumarin 6 (C6)-loaded liposomes. The results of ATR-FTIR, 1HNMR, and 13CNMR demonstrated successful formation of CAC. A molecular docking study showed efficient binding affinities rather than carnitine to the active site of four carnitine transporters. Liposomal formulations possessed spherical morphology with a mean particle size range of 112-138 nm, narrow size distribution, and negative surface charge. All formulations had low cytotoxicity at 0.5 mg/ml, but high cytotoxicity at around 2.5 mg/ml. The lowest IC50 was obtained for CAC modified liposomes. CAC + PEG-modified liposomes had the highest cellular uptake. In conclusion, CAC + PEG modification of liposomes is an effective approach for increasing A549 cellular uptake, with low cytotoxicity at commonly applied liposome concentrations. The elevated uptake may be due to the involvement of the organic cation transporter, cationic structure, and the metabolic preference of CAC in cancer cells." @default.
- W3204223881 created "2021-10-11" @default.
- W3204223881 creator A5003793995 @default.
- W3204223881 creator A5009670303 @default.
- W3204223881 creator A5029131650 @default.
- W3204223881 creator A5056098336 @default.
- W3204223881 creator A5061890110 @default.
- W3204223881 creator A5066654365 @default.
- W3204223881 creator A5072363891 @default.
- W3204223881 date "2021-11-01" @default.
- W3204223881 modified "2023-10-18" @default.
- W3204223881 title "Surface modification with cholesteryl acetyl carnitine, a novel cationic agent, elevates cancer cell uptake of the PEGylated liposomes" @default.
- W3204223881 cites W1034346829 @default.
- W3204223881 cites W1859037964 @default.
- W3204223881 cites W1887624773 @default.
- W3204223881 cites W1976053959 @default.
- W3204223881 cites W1987136886 @default.
- W3204223881 cites W1989346639 @default.
- W3204223881 cites W2000188433 @default.
- W3204223881 cites W200185773 @default.
- W3204223881 cites W2001974499 @default.
- W3204223881 cites W2004992318 @default.
- W3204223881 cites W2005262643 @default.
- W3204223881 cites W2014760202 @default.
- W3204223881 cites W2017791788 @default.
- W3204223881 cites W2024696692 @default.
- W3204223881 cites W2042487849 @default.
- W3204223881 cites W2044269322 @default.
- W3204223881 cites W2047482521 @default.
- W3204223881 cites W2047884627 @default.
- W3204223881 cites W2052227307 @default.
- W3204223881 cites W2055180860 @default.
- W3204223881 cites W2055675213 @default.
- W3204223881 cites W2079162811 @default.
- W3204223881 cites W2094458603 @default.
- W3204223881 cites W2096726540 @default.
- W3204223881 cites W2104812418 @default.
- W3204223881 cites W2110779321 @default.
- W3204223881 cites W2113362613 @default.
- W3204223881 cites W2134866080 @default.
- W3204223881 cites W2140750582 @default.
- W3204223881 cites W2155821409 @default.
- W3204223881 cites W2165595068 @default.
- W3204223881 cites W2187145161 @default.
- W3204223881 cites W2591435203 @default.
- W3204223881 cites W2593351131 @default.
- W3204223881 cites W2615540589 @default.
- W3204223881 cites W2765269091 @default.
- W3204223881 cites W2791549657 @default.
- W3204223881 cites W2793452092 @default.
- W3204223881 cites W2794453923 @default.
- W3204223881 cites W2797455782 @default.
- W3204223881 cites W2800512413 @default.
- W3204223881 cites W2883965199 @default.
- W3204223881 cites W2897121101 @default.
- W3204223881 cites W2903715092 @default.
- W3204223881 cites W2946277620 @default.
- W3204223881 cites W2946446720 @default.
- W3204223881 cites W2966620525 @default.
- W3204223881 cites W2980366442 @default.
- W3204223881 cites W2981770708 @default.
- W3204223881 cites W2981801813 @default.
- W3204223881 cites W2995385432 @default.
- W3204223881 cites W3004116266 @default.
- W3204223881 cites W3004806453 @default.
- W3204223881 cites W3005142579 @default.
- W3204223881 cites W3036390256 @default.
- W3204223881 cites W3041739832 @default.
- W3204223881 cites W3041761636 @default.
- W3204223881 cites W3151708782 @default.
- W3204223881 cites W3159453988 @default.
- W3204223881 cites W4237242887 @default.
- W3204223881 cites W81527160 @default.
- W3204223881 doi "https://doi.org/10.1016/j.ijpharm.2021.121148" @default.
- W3204223881 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34600054" @default.
- W3204223881 hasPublicationYear "2021" @default.
- W3204223881 type Work @default.
- W3204223881 sameAs 3204223881 @default.
- W3204223881 citedByCount "5" @default.
- W3204223881 countsByYear W32042238812021 @default.
- W3204223881 countsByYear W32042238812022 @default.
- W3204223881 countsByYear W32042238812023 @default.
- W3204223881 crossrefType "journal-article" @default.
- W3204223881 hasAuthorship W3204223881A5003793995 @default.
- W3204223881 hasAuthorship W3204223881A5009670303 @default.
- W3204223881 hasAuthorship W3204223881A5029131650 @default.
- W3204223881 hasAuthorship W3204223881A5056098336 @default.
- W3204223881 hasAuthorship W3204223881A5061890110 @default.
- W3204223881 hasAuthorship W3204223881A5066654365 @default.
- W3204223881 hasAuthorship W3204223881A5072363891 @default.
- W3204223881 hasConcept C10138342 @default.
- W3204223881 hasConcept C104317684 @default.
- W3204223881 hasConcept C109316439 @default.
- W3204223881 hasConcept C12554922 @default.
- W3204223881 hasConcept C155887181 @default.
- W3204223881 hasConcept C162324750 @default.
- W3204223881 hasConcept C185154212 @default.
- W3204223881 hasConcept C185592680 @default.